Blood-borne vCJD risk: in UK and other European populations Sheila M. Bird MRC Biostatistics Unit, CAMBRIDGE.

Slides:

Advertisements

Similar presentations

Creutzfeldt-Jakob Disease Classic CJD occurs worldwide at 1-2 cases per million population per year In people over 50, the annual rate is about 3.4 per.

Advertisements

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.

Saotharlann Náisiúnta Tagartha Viris UCD UCD National Virus Reference Laboratory Dr. Jeff Connell Assistant Director National Virus Reference Laboratory.

Removal of Prions by Plasma Fractionation Processes

Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.

Spectrum 2007 Overview and New Changes UNAIDS Reference Group on Estimates, Model and Projections 2007.

Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.

1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.

PRION DISEASES BLOOD INFECTIVITY ISSUES Richard Knight NCJDSU.

Research on Pre-Movement Testing in Ireland Tracy Clegg Centre for Veterinary Epidemiology and Risk Analysis, University College Dublin.

HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,

Predicting an Epidemic A Quantitative Assessment of TSE Sampling Data to Predict Outbreak Magnitude Aspen Shackleford HONR299J.

Analysis to Inform Decisions: Evaluating BSE Joshua Cohen and George Gray Harvard Center for Risk Analysis Harvard School of Public Health.

Mad Cow Disease 袁聖甯黃竹瑄鄧雯心. What is Mad Cow Disease ? A kind of transmissible spongiform encephalopathies (TSE) Occurs in many mammals, including human.

CJD Overview Bob Will, National CJD Surveillance Unit, Edinburgh, UK Associazione Italiana Encefalopatie da Prion Milano 3 Ottobre 2009.

Are humans susceptible?

Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.

VARIANT CJD AN UPDATE DR. HESTER WARD National CJD Surveillance Centre Edinburgh, UK

Bovine Spongiform Encephalopathy Luke VanNatter Carrie Pell Amy Richwine Scott Inskeep Kristina Anderson.

Mad Cow Disease. Effects of Mad Cow disease Mad cow disease, or bovine spongiform encephalopathy (BSE), is a fatal brain disorder that occurs in cattle.

Harvard Center for Risk Analysis Evaluation of the Potential for BSE in the United States Joshua T. Cohen Keith Duggar George M. Gray Silvia Kreindel Harvard.

Canadian and U.S. BSE Risk Steven Anderson, Ph.D, MPP Office of Biostatistics & Epidemiology Center for Biologics Evaluation & Research U.S. Food & Drug.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Infectious Disease Epidemiology Sharyn Orton, Ph.D. American Red Cross, Rockville, MD Suggested reading: Modern Infectious Disease Epidemiology (1994)

21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?

Prion Diseases Microbes and Society Fall What is a Prion? Prion- small proteinaceous infectious particles which resist inactivation by procedures.

Evolution of the Mad Cow Disease in the United States Denish Moorthy, Eugene Shubnikov, Ron LaPorte The Supercourse Network of the Global Health University.

Prion-related diseases: EU medico-scientific and regulatory issues, problems, and recommendations William P. Charteris The Consultant’s.

BOVINE SPONGIFORM ENCEPHALOPATHY (BSE) or “Mad Cow Disease”: Cause and effect on the beef market. Name: Odette K Busambwa.

 Caused by parasite › Transmitted by mosquito › Once injected into the human, the parasite grows and multiples first in the liver and then the red blood.

Transmissible Spongiform Encephalopathies Ryan Maddox, MPH Creutzfeldt-Jakob Disease Surveillance Unit Division of Viral and Rickettsial Diseases National.

Health registers as a ressource for research Preben Bo Mortensen Director, Professor, DrMedSc National Centre for Register-based Research Aarhus University.

Canada’s BSE Story Presentation to the Ontario Association of Bovine Practitioners November 6, 2003.

The Pathological Protein, Chapters 8-9 Rhiannon Aguilar HONR299J March 27, 2014.

Prions: Proteins Gone Bad

Investigation of vCJD in Leicestershire Dr Philip Monk & Dr Gerry Bryant.

Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.

BSE/TSE measures – state of play and future work Plenary of the Advisory Group on the Food Chain, Animal and Plant Health 19 December 2008.

January 2002 WHO/CSR/APH Efforts and needs for global control of BSE and vCJD Maura N. Ricketts MD MHSc FRCPC WHO/CDS/CSR/EPH.

Proposed algorithm for approval of human TSE tests in Europe.

BSE: World Situation and USDA Response FDA TSE Advisory Committee Silver Spring, MD October 14, 2004 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA,

The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.

Chronic Wasting Disease (CWD) David Litts. What is it? Prions (infectious incomplete protein) Prions (infectious incomplete protein) Creutzfeldt-jakob.

 Foreign Sources of Infection To − Vi Nguyen. Foreign Infection  Preventable environmental source of infection  Remove infectious material, epidemic.

 slowly progressive, degenerative, and fatal disease affecting the central nervous system of adult cattle.  abnormal version of a protein normally found.

Mad Cow Disease Making sense of the headlines by Trevor Murdock.

Variant Creutzfeldt-Jakob Disease Impact on U.S. Military Service Members Lt. Col. David Lincoln Deputy Director Armed Services Blood Program Office Unclassified.

RISK COMMUNICATION APPROACH TSEAC 15 December 2006 Mark Weinstein, Ph.D. FDA, Center for Biologics Evaluation and Research.

Very low CHD mortality among men aged in several states in the United States Akira Sekikawa, MD, PhD, PhD Lewis H Kuller, MD, DrPH Department of.

Draft Risk Assessment for UK manufactured Factor XI and Potential vCJD Exposure Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center.

The History of Chronic Wasting Disease Dr. Trent Bollinger, CCWHC One World, One Health Symposium Sept. 29, 2004.

BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.

Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.

Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.

VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.

MAD COW DISEASE Anna Hoffmann. What is it?  Mad cow disease, or bovine spongiform encephalopathy (BSE), is a transmissible, slowly progressive fatal.

Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.

David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.

1 A Simulation Model to Quantify the Spread of BSE in the United States Joshua Cohen and George Gray Harvard Center for Risk Analysis Harvard School of.

FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Mad cow disease The 2001 biology project Made by TommyChan.

Official investigation on a case of BSE on the example of a EU member state I Ivan Ambrožič, DVM, MSc Kiev 4. – 5- April 2011.

Legal framework of TSE surveillance Workshop on Prevention, Control and Eradication of Transmissible Spongiform Encephalopathies (TSE) Serbian Ministry.

Community-wide outbreak of hepatitis A in Latvia in 2008 Jurijs Perevoščikovs Head, Department of Epidemiological Surveillance of Infectious Diseases State.

(Bovine spongiform encephalopathy)

Bovine Spongiform Encephalopathy Variant Creutzfeldt-Jakob disease

Brain Trust Chapt 22: Origins

Frequently Asked Questions About BSE

Chronic Wasting Disease

Presentation transcript:

Blood-borne vCJD risk: in UK and other European populations Sheila M. Bird MRC Biostatistics Unit, CAMBRIDGE

BSE cascade... to end 2004 Human Dietary BSE exposure: consider UK exports of bovine carcasses (60% to France: C-H & A), UK exports of contaminated feed, UK exports of infected live-stock [GBR III... ] UK: France: carcasses other = 20: 1: 0.67 (% male?) vCJD clinical cases (presumed dietary exposure: 90m/161) 152: 9: Ireland (2), Italy (1), Saudi (1) Canada (1), USA (1) = 7... Blood-borne vCJD exposure: consider UK: France: other exports of pre/sub-clinical vCJDs, & of contaminated blood/products...

Brief history: BSE{Nov. 1986} & vCJD BSE projections too low: maternal transmission et vive la France vCJD projections: news & dietary BSE exposure by birth- cohort & gender Geographical BSE Risk 

BSE Controls after November 1986: infectivity highest in brain, spinal cord [& DRG] Slaughter-compensate & Feed Ban: Aug SBO legislation (brain, spinal cord) : Nov additions/amendments... SVS inspections... MRM from vertebral columns: ended December 1995 vCJD announced: 20 March 1996 Recovery of head meat: ended March 1996 Over Thirty Month Scheme [OTMS]: April 1996 Real Feed Ban: 1 August 1996 [UK], January 2001[EU]

Remit: National CJD Surveillance Unit, 1990 To alert to any changes in age-specific incidence, occupational distribution, or dietary correlates of CJD that might suggest humans were affected by exposure to BSE Presentation, if it happened at all, was more likely to be atypical, but could not be described in advance

It’s official, mad cow disease can kill you! 10 cases of variant CJD in UK young age at onset longer clinical course distinctive neuropathology methionine homozygosity

April 1996: Ministry vets spurn calls to pass on data from dam-calf experiments... 10% maternal transmission risk within 6 months of BSE onset in dam BSE Inquiry: CMO letters

Nature, August 1996 Transmission dynamics and epidemiology of BSE in British cattle Anderson RM, Donnelly CA et al. Sacred cows, science and uncertainties David CG Skegg Mean BSE incubation period = 5 years

BSE incidence incubation age-specific slaughter/export = BSE affected *BSE incidence curve: access to contaminated feed maternal transmission? other exposure? *Age-specific slaughter/export: dairy or beef herd BSE-infected?

BSE projections Back-calculation from clinical BSE cases  serious under-estimation of BSE infections No under-reporting of BSE cases after 1988 No diversion of BSE cases into OTMS No differential survival if BSE-infected No exposure except maternal after August 1996

vCJD projections ~ news! Back-calculation from clinical vCJD cases  beware ! Projections reigned in: vast to < 1000 to... < 400 Dietary BSE exposure by birth-cohort: explains young age, anticipate male excess re dietary vCJD ?... Valleron !

UK dietary exposure to BSE: infectivity from beef MRM & head meat Birth-cohort: & vCJDs Onsets before 2001 Median infectivity [Bo ID50s] Post-1969: 64 83, , – 1969: , , 600 Pre-1940: 1 39, , 200

Dietary exposure to BSE: Cooper & Bird; Chadeau-Hyam & Alperovitch Birth-cohort: & vCJDs Onsets before 2004 UK France Median infectivity [Bo ID50s] UK France Post-1969: , , – 1969: , , 400 Pre-1940: 1 0 (+1 blood-borne) 86, 500 5, 400

birth cohort: intrinsic age-dependent susceptibility [Valleron] Period of birth vCJD patients ‘Best’: without age- susceptibility Add: 0.06 exp. decay after 15 years 1940– = = ( 4 – 13) 7 ( 2 – 11) ( 6 – 16) 12 ( 7 – 18) ( 8 – 17) 19 (14 – 27)

Spectre of sub-clinical BSE infections: Differential by birth-cohort? Blood/operation-transmissible?

vCJD projections ~ latest Chadeau-Hyam & Alperovitch (Int. J. Epid.) BSE dietary exposure in UK: France = 20:1 vCJD incidence UK: France = 152:9 = 17:1 {dietary} vCJD projections France = 33 in total {Valleron/C & B: 0.06} vCJD projections UK... “under 600” {individual in birth cohort required more (* 1.5) infectious units to be infected than in post-1969 cohort. Also, note: species barrier re dietary BSE exposure}

Rapid post-mortem BSE/TSE testing 1999: Switzerland (fallen stock & 5% normal slaughter ~ BSE tested); OTMS 2000: France & N. Ireland (risk stock), UK (OTMS); Swiss 2000: EU approved 3 BSE tests (out of 4: Nature, 1999) 2000: Geographical BSE Risk [GBR III = BSE likely, or confirmed at low level] 2001: EU’s Requirements for Statistically Authoritative BSE/TSE Surveys

Active BSE surveillance: 2001 European Union BSE positivity ~ 10 to 15 times higher in risk stock than normal slaughter bovines aged over 30m THREE-SUM = # BSE positives in risk stock + # clinical BSEs + # BSE positives at normal slaughter

Jan-Apr BSE surveillance in 2004: & BSE positive rate per 1 million tested Member State EU15 - UK # tested Adult cattle 36.2m Clinical BSE 39 Risk stock: & rate pmt 101 *: K Normal kill: & rate pmt 47 : 16 2,959K UK # tested 4.9m : K Not applicable {JW = “60”} New MS # tested 5.6m 0 6: 95 63K 6: K

Late-stage BSE under-estimated:  UK BSE infection incidence * 3 BSE testing in OTMS BSE positives in 10,032 OTMS bovines aged 5 years+  2700 BSE positives in OTMS, when UK had only 1400 clinical BSEs in 2000  BSE infections * 3

Sheep scrapie (plus genotype)

Active TSE surveillance in sheep: ,000 adult sheep & 6,000 fallen sheep per MS Genotyping: TSE positives [& 6 controls] & ‘random’ sample of 500 adult sheep Early monitoring [year 1]... 4 TSE positives in ‘scrapie-resistant’ ARR/ARR sheep! Re- appraisal of ARQ/ARQ genotype (accounted for 515/1310 positives: 39%)

Rapid post-mortem PrP testing: in humans?

Probable blood-borne vCJD transmission: “study-detected” Donation = March 1996 Donor’s vCJD onset = 1999 [~ 3yrs] Recipient’s vCJD onset = autumn 2002 [6.5yrs] Recipient death (undiagnosed) = autumn 2003 vCJD-blood recipient = MM, born pre-1940

Probable blood-borne vCJD transmission: “autopsy-detected” Donation = ? mid 1999 Donor’s vCJD onset = ? end 2000 [ ~ 1.5 yrs] Recipient’s vCJD onset = no: sub/pre-clinical “Dr.-alerted re recipient’s status: medico-legal” PM-detected non-clinical vCJD = July 2004 [5yrs] vCJD blood-recipient = MV, born pre-1940

Testing for abnormal prion in human tonsil/appendix/spleen

Abnormal PrP in tonsil/appendix Unlinked Anonymous Testing of stored tissue: , mainly aged years at operation. Positive in 1 st 8,000 tested... Finally, 3 Positive in 12,674 tested (two atypicals...) vCJD-projections-prior: expected 1 in 40,000 Conflict: vCJD cases  surveillance National tonsil collection started in

vCJD projections ~ latest Clarke & Ghani (J. Royal Society Interface) Projected UK Prevalent case numbers (2004+) infections:04 vCJD cases only 70 ( ) * Clinical & survey 133 ( 32 – 3780) 140 (36 –10K) Sub-clinical carrier II 69 ( ) 5000 (1K-13K) Wider genetic susceptibility... ? Sub-clinical BSE infection transmissible by blood

Limit human-to-human vCJD & acquire key data Rural analogy  now consider Attributable testing for abnormal prion at: Tonsillectomy Appendicectomy etc * Autopsy under 55 years of age & Permission-in-life for post-mortem testing in alerted at-vCJD-risk patients

Limit human-to-human vCJD & acquire key data  rural analogy Experimental BSE/scrapie transfusion risks in 20+ sheep = 10% to 20% Humans’ vCJD blood transfusion risk to 5-year survivors = 2/17 or 2/ (17- 5 {no autopsy}) = 2/17 (about 10%) to 2/12 (about 17%)

Acquire key data: without consent at autopsy Test for subclinical vCJD at autopsy (sv/A) [sv/A: by age-group, sex and genotype  prevalence] If subclinical vCJD, alert recipient-networks (blood, products, tissues, surgical, needle-stick, maternal) Recipient-networks: a) prevent onward transmission, b) contribute key data to document their exposure risk

Acquire key data about ‘transmission-risk’ Permission-in-life for post-mortem testing in alerted at-vCJD-risk patients (BMJ list, 30 March 1996): Blood transfusion recipients; Blood product recipients Tissue recipients; Surgical “recipients” Needle-stick BSE/vCJD/subclinical vCJD “recipients” Child born within y years of vCJD death in mater/pater Sexual risk... PM-detected subclinical vCJD in those vCJD-exposed at least 5 years previously / # PM-ed and/or who were vCJD-exposed at least 5 years previously = “sv5/PM5”

Detectability & Affordability A worse case (10% transmission risk): 500,000 tests on operative tissue  100 sub-clinical vCJDs (10 donors, 40 recipients, 10 survive 5 years, 1)  one avoidable (blood-borne) vCJD transmission Even if screening cost £200 a tissue... cost is a 10 th only of OTMS to prevent one cattle-human vCJD IF transmission risks were 100 times less (0.1% versus 10%), not even £1000 million would suffice for their reduction...